Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for IRulya Therapeutics Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$39.53+1.0%Nov 11 close
Reported results on November 11, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 14, 2026